Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator-Reference-Cited by-同舟云学术

Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator

Published:2024-04-25 Issue:3 Volume:168 Page:487-494
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Matsuda Ryosuke,Maeoka Ryosuke,Morimoto Takayuki,Nakazawa Tsutomu,Morisaki Yudai,Yokoyama Shohei,Kotsugi Masashi,Takeshima Yasuhiro,Yamada Shuichi,Nishimura Fumihiko,Park Young-Soo,Nakagawa Ichiro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11060-024-04692-5.pdf

Reference31 articles.

1. Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Koga T, Sasaki N, Kinoshita M, Nagane M, Arakawa Y, Yoshimoto K, Shibahara I, Shinojima N, Asano K, Tsurubuchi T, Sasaki H, Asai A, Sasayama T, Momii Y, Sasaki A, Nakamura S, Kojima M, Tamaru JI, Tsuchiya K, Gomyo M, Abe K, Natsumeda M, Yamasaki F, Katayama H, Fukuda H (2023) Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro Oncol 25:687–698. https://doi.org/10.1093/neuonc/noac246

2. (2017) Brain tumor registry of Japan (2005–2008). Neurol Med Chir (Tokyo) 57:9–102. https://doi.org/10.2176/nmc.sup.2017-0001

3. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17. https://doi.org/10.1016/0360-3016(92)90538-s

4. Luo Q, Yang C, Fu C, Wu W, Wei Y, Zou L (2021) Prognostic role of blood markers in primary central nervous system lymphoma patients treated with high-dose methotrexate-based therapy. Front Oncol 11:639644. https://doi.org/10.3389/fonc.2021.639644

5. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosee PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Ruda R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gorlov JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study G (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217-227. https://doi.org/10.1016/S2352-3026(16)00036-3